AstraZeneca
12,032.00 GBpChange from previous close: −2.02%Absolute change: −248.00 GBp
At a glance
- Revenue growth
- +8.63%
- 2025 vs 2024
- Net income growth
- +45.34%
- 2025 vs 2024
- Net margin
- 17.4%
- 2024: 13.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
| Cost of revenue | 10,746 | 9,638 | 8,045 | 8,641 | 12,005 |
| Gross profit | 47,993 | 44,435 | 37,766 | 35,710 | 25,412 |
| Selling, general and administrative | 20,072 | 19,453 | 18,036 | 17,460 | 14,673 |
| Research and development | 13,851 | 12,243 | 10,306 | 9,669 | 8,049 |
| Operating income | 14,292 | 12,929 | 9,699 | 8,812 | 2,897 |
| EBIT | 14,292 | 12,929 | 9,699 | 8,812 | 2,897 |
| EBITDA | 19,280 | 17,567 | 14,275 | 13,744 | 6,701 |
| Interest expense | 1,365 | 1,403 | 1,219 | 917 | 776 |
| Pre-tax income | 12,402 | 8,691 | 6,899 | 2,501 | -265 |
| Income tax | 2,169 | 1,650 | 938 | -792 | -380 |
| Net income | 10,225 | 7,035 | 5,955 | 3,288 | 112 |
| Net income to common shareholders | 10,225 | 7,035 | 5,955 | 3,288 | 112 |
| Basic EPS | 6.60 | 4.54 | 3.84 | 2.12 | 0.08 |
| Diluted EPS | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 |
| Average shares (basic) | 1,550 | 1,550 | 1,549 | 1,548 | 1,418 |
| Average shares (diluted) | 1,562 | 1,563 | 1,562 | 1,560 | 1,427 |
| Dividend per share | 3.20 | 3.10 | 2.90 | 2.90 | 2.87 |